Clinical ResearchPharmacotherapy of HDL and LDLEfficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density Lipoprotein Cholesterol Levels
Abbreviations and Acronyms
Cited by (0)
This study was sponsored by Pfizer Inc. Conflicts of interest: Dr. Michael H. Davidson—Research Grants: Abbott Laboratories, AstraZeneca, KOS, Merck, Merck/Schering Plough, Pfizer, Reliant Pharmaceuticals, Roche, Sankyo Pharma, and Takeda Pharmaceuticals. Speakers’ Bureau: Abbott Laboratories, AstraZeneca, KOS, Merck, Merck/Schering-Plough, Pfizer, Reliant Pharmaceuticals, Sankyo Pharma, and Takeda Pharmaceuticals. Consultant/Advisory Board: Abbott Laboratories, AstraZeneca, KOS, Merck, Merck/Schering-Plough, Pfizer, Reliant Pharmaceuticals, Roche, Sankyo Pharma, Sumimoto Pharmaceuticals, and Takeda Pharmaceuticals. Dr. James M. McKenney—Speaking Honorarium: AstraZeneca, KOS, Merck/Schering Plough, Pfizer, Reliant Pharmaceuticals, and Takeda Pharmaceuticals. Consultant/Advisory Board: AstraZeneca, KOS, Microbia, Pfizer, and Sankyo Pharma. Research Grants (awarded to company, not individual): AstraZeneca, GSK, KOS, Merck, Pfizer, Roche, Schering Plough, and Takeda Pharmaceuticals. Dr. James H. Revkin—Ownership Interest: Pfizer Stock/Options. Institution/Employer: Pfizer. Adjunct Faculty: Yale University. Dr. Charles L. Shear—Institution/Employer: Pfizer.